Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Neurology and Therapy
Cardiovascular (CV)
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
New England Journal of Medicine
Acute Hepatic Porphyria (AHP)
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
Journal of Hepatology
Transthyretin Amyloidosis (ATTR)
Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy
Expert Opinion on Pharmacotherapy
Primary Hyperoxaluria Type 1 (PH1)
Quantification of oxalate by novel LC-MS/MS: assay development, validation and application in lumasiran clinical trials
Bioanalysis
Acute Hepatic Porphyria (AHP)
Pharmacokinetic-Pharmacodynamic Model of Urinary δ-Aminolevulinic Acid Reduction After Givosiran Treatment in Patients with Acute Hepatic Porphyria
CPT: Pharmacometrics & Systems Pharmacology
Primary Hyperoxaluria Type 1 (PH1)
Estimating health state utilities in primary hyperoxaluria type 1: a valuation study
Journal of Medical Economics
Acute Hepatic Porphyria (AHP)
Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria
Clinical Pharmacokinetics
Transthyretin Amyloidosis (ATTR)
Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study
European Journal of Heart Failure
